GLENMARK PHARMACEUTICALS
Back to Cashflow Statement
|
GLENMARK PHARMACEUTICALS Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹-2,709 Cr | ₹787 Cr | ₹-3,906 Cr | ₹-77 Cr | ₹-520 Cr |
What is the latest Cash Flow from Financing Activities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2026 | ₹-2,709 Cr |
| Mar2025 | ₹787 Cr |
| Mar2024 | ₹-3,906 Cr |
| Mar2023 | ₹-77 Cr |
| Mar2022 | ₹-520 Cr |
How is Cash Flow from Financing Activities of GLENMARK PHARMACEUTICALS Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2026 | ₹-2,709 Cr | Negative | |
| Mar2025 | ₹787 Cr | Positive | |
| Mar2024 | ₹-3,906 Cr | Negative | |
| Mar2023 | ₹-77 Cr | Negative | |
| Mar2022 | ₹-520 Cr | - | |
Compare Cash Flow from Financing Activities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹65,611.5 Cr | -0.6% | 5.8% | 11% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹456,114.0 Cr | -1.2% | -2.2% | 15.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹227,958.0 Cr | 1% | 16.3% | 39.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹189,990.0 Cr | 3.2% | -0.8% | 38.6% | Stock Analytics | |
| CIPLA | ₹116,141.0 Cr | -0.9% | 1.6% | -9.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,604.4 Cr | -1.7% | -0.1% | -6.5% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -0.6% |
5.8% |
11% |
| SENSEX | -0.7% |
0.1% |
-3.4% |
You may also like the below Video Courses